Yaz Birth Control Trial Updates

2012 was designed to be a great year in drug development of Yaz birth control with more than 10,000 trials against Bayer on complaints of violations of the contraceptive pill Yasmin / YAZ (What are birth control pills?). The first trial was to begin this month with respect to Illinois  and Yaz birth control (Who is Yaz?).

Unfortunately, a district judge to Yaz birth control  of the United States adjourned the trial to comply with the order instead of the lawyers of both parties with a mediator appointed to Yaz birth control by the court. The goal, said the judge, the viability of the provision, "the settlements in this lawsuit for Yaz birth control ."

The plaintiffs allege that Bayer f knew his family contraceptive  Yaz birth control   (which contains the progestin drospirenone) patients sales are at higher risk of blood clots from Yaz birth control , or marketed the drug safer than competition are birth control pills.

According to a lawyer for the plaintiffs, by changing the format of the test came to mediation after the protests of the defendants of Yaz birth control . He said: "Bayer wanted to go to court and the judge will decide if they wanted to find a solution outside the courtroom."

He added: "We are ready to try cases of these Yaz birth control, but we are also willing to talk, if Bayer wants to try in good faith."

The mediator is a law professor at George Washington University. Fortunately, it seems to come with sound knowledge and experience in mediating disputes  Yaz birth control . The president of a law firm based in New Jersey, said the professor, "has a keen sense of right and wrong, and he works for a reasonable review of the case about Yaz birth control that everyone can live."

The plaintiffs and their lawyers have a solid case, and the evidence against Bayer. Considering the evidence is not surprising that Bayer for Yaz birth control did not want to go to court. It will be interesting to see what effect, if any, will be held this mediation.

A number of studies abotu Yaz birth control have yielded conflicting results on their security risks, with a significantly increased risk of development of blood clotting and increase the other. In December, an FDA expert panel has evaluated the data and labeling the group recommended changes to clarify the potential risk of blood clots. The Committee approved the drug benefit-risk profile, but with a vote of 15-11.